Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

Kynam Capital Management, LP

CIK 0001907884
$1.62B
Reported AUM
37
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · Kynam Capital Management, LP · Q1 2026

AI · grounded in 13F

Kynam Capital Management, LP closed its position in TYRA for a reduction of $41.1M. The fund also exited positions in CGON and DVAX, totaling $39.3M and $21.2M respectively. On the buy side, the fund established new positions in URGN for $40.4M and LEGN for $28.5M. Additionally, it increased its stake in TVTX by 368%.

Portfolio · Q1 2026

SNDX$188.1MCLDX$185.3MPCVX$169.8MCOGT$155.4MVERA$136.7MBEAM$87.7MTVTXCTMXBCRXVRDNCGEMURGNOther$371.0MKL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1SNDXSYNDAX PHARMACEUTICALS INC$19.05-2.21%90.98%8.98%$188.1M11.60%HELD
2CLDXCELLDEX THERAPEUTICS INC NEW$38.06-1.12%70.11%-28.30%$185.3M11.43%HELD
3PCVXVAXCYTE INC$54.08-3.36%67.08%110.33%$169.8M10.48%HELD
4COGTCOGENT BIOSCIENCES INC$38.93-5.88%248.33%379.59%$155.4M9.59%HELD
5VERAVERA THERAPEUTICS INC$32.10-2.87%54.11%119.03%$136.7M8.43%HELD
6BEAMBEAM THERAPEUTICS INC$25.52-3.66%36.01%-76.91%$87.7M5.41%HELD
7TVTXTRAVERE THERAPEUTICS INC$55.89-2.43%257.58%156.02%$72.0M4.44%HELD
8CTMXCYTOMX THERAPEUTICS INC.$3.10-5.49%33.40%-38.77%$70.6M4.35%HELD
9BCRXBIOCRYST PHARMACEUTICALS INC$8.98-2.81%12.96%-43.59%$54.1M3.34%HELD
10VRDNVIRIDIAN THERAPEUTICS INC$18.92-4.92%14.30%48.73%$45.8M2.83%HELD
11CGEMCULLINAN THERAPEUTICS INC$16.50-5.82%115.25%-41.50%$44.3M2.73%HELD
12URGNUROGEN PHARMA LTD$38.24-6.94%99.90%120.09%$40.4M2.49%HELD
13KALVKALVISTA PHARMACEUTICALS INC$36.7M2.26%HELD
14APLSUSDAPELLIS PHARMACEUTICALS INC$33.2M2.05%HELD
15LEGNLEGEND BIOTECH CORP$18.55-2.62%-52.19%-51.55%$28.5M1.76%HELD
16MBXMBX BIOSCIENCES INC$65.93-0.80%381.16%188.91%$27.9M1.72%HELD
17IMCRIMMUNOCORE HLDGS PLC$33.81-0.18%1.03%-3.56%$26.7M1.65%HELD
18STROSUTRO BIOPHARMA INC$24.17-2.62%206.42%-88.57%$21.7M1.34%HELD
19RVMDREVOLUTION MEDICINES INC$187.53-2.41%424.62%560.61%$20.2M1.24%HELD
20BNRBURNING ROCK BIOTECH LTD$8.900.56%56.08%-95.25%$19.8M1.22%HELD
21SLNOSOLENO THERAPEUTICS INC$18.7M1.16%HELD
22NRIXNURIX THERAPEUTICS INC$23.21-1.57%113.41%-26.81%$18.5M1.14%HELD
23PHVSPHARVARIS N V$32.62-3.72%63.35%61.81%$18.1M1.12%HELD
24EVMNEVOMMUNE INC$11.25-0.88%-38.86%-34.26%$14.4M0.89%HELD
25RLAYRELAY THERAPEUTICS INC$18.83-3.19%453.27%-41.96%$14.2M0.87%HELD
26GERNGERON CORP$1.29-3.73%14.53%-7.59%$10.2M0.63%HELD
27ENGENE HOLDINGS INC$9.2M0.57%HELD
28DSGNDESIGN THERAPEUTICS INC$12.18-3.49%226.18%-20.74%$8.3M0.51%HELD
29WVEWAVE LIFE SCIENCES LTD$5.51-4.34%-35.52%-12.09%$7.0M0.43%HELD
30CLYMCLIMB BIO INC$11.90-1.49%720.69%-33.82%$6.9M0.42%HELD
31AMRNAMARIN CORP PLC$14.260.21%$6.8M0.42%HELD
32BHVNBIOHAVEN LTD$13.50-2.32%$5.9M0.37%HELD
33PRLDPRELUDE THERAPEUTICS INC$4.60-8.91%$5.4M0.34%HELD
34CRBUCARIBOU BIOSCIENCES INC$1.46-3.31%$4.8M0.29%HELD
35ALECALECTOR INC$1.51-6.79%$4.3M0.27%HELD
36PRQRPROQR THRAPEUTICS N V$1.72-3.37%$2.5M0.16%HELD
37CADLCANDEL THERAPEUTICS INC$10.011.42%$980K0.06%HELD

Source: SEC EDGAR · accession 0001907884-26-000007. 13F discloses long positions only — shorts, foreign equities, and options are excluded.